2-Anilino-4-(benzimidazol-2-yl)pyrimidines - A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines

European Journal of Medicinal Chemistry

Volumn 53, Issue , 2012, Pages 254-263

  Determann, Renate ^a   Dreher, Jan ^a   Baumann, Knut ^a   Preu, Lutz ^a   Jones, Peter G ^a   Totzke, Frank ^b   Schächtele, Christoph ^b   Kubbutat, Michael H G ^b   Kunick, Conrad ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b PROQINASE GMBH   (Germany)

Author keywords

Anilinopyrimidine; Benzimidazol; Cancer; COMPARE; Multikinase inhibitor

Indexed keywords

1,3 DIMETHYL 7 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIDO[2,3 DEXTRO]PYRIMIDINE-2,4 (1H,3H)DIONE; 2 ANILINO 4 (BENZIMIDAZOL 2 YL)PYRIMIDINE DERIVATIVE; 2 CHLORO 4 [[4 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIMIDIN 2 YL]AMINO]PHENOL; 2 METHOXY 5 [[4 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIMIDIN 2 YL]AMINO]PHENOL; 3 [[4 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIMIDIN 2 YL]AMINO]PHENOL; 4 (1 METHYL 1H BENZIMIDAZOL 2 YL) N (4 CHLOROPHENYL)PYRIMIDIN 2 AMINE; 4 (1 METHYL 1H BENZIMIDAZOL 2 YL) N (4 METHYLPHENYL)PYRIMIDIN 2 AMINE; 4 (1 METHYL 1H BENZIMIDAZOL 2 YL) N [4 (MORPHOLIN 4 YL)PHENYL]PYRIMIDIN 2 AMINE; 4 (1 METHYL 1H BENZIMIDAZOL 2 YL) N PHENYLPYRIMIDIN 2 AMINE; 4 [[4 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIMIDIN 2 YL]AMINO]PHENOL; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AURORA B KINASE; FOCAL ADHESION KINASE; N (4 ETHOXYPHENYL) 4 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIMIDIN 2 AMINE; N (4 METHOXYPHENYL) 4 (1 METHYL 1H BENZIMIDAZOL 2 YL)PYRIMIDIN 2 AMINE; POLO LIKE KINASE 1; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84861613367     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.04.007     Document Type: Article

References (55)

1. S. Grant Therapeutic protein kinase inhibitors Cell. Mol. Life Sci. 66 2009 1163 1177
2. W. Ma, and A. Adjei Novel agents on the horizon for cancer therapy CA Cancer J. Clin. 59 2009 111 137
3. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
4. L. Gossage, and T. Eisen Targeting multiple kinase pathways: a change in paradigm Clin. Cancer Res. 16 2010 1973 1978
5. R. Morphy Selectively nonselective kinase inhibition: striking the right balance J. Med. Chem. 53 2010 1413 1437
6. A. Petrelli, and S. Giordano From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage Curr. Med. Chem. 15 2008 422 432
7. P. McCormack, and S. Keam Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia Drugs 71 2011 1771 1795
8. D.B. Mendel, A.D. Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.O. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J.M. Cherrington In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin. Cancer Res. 9 2003 327 337
9. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, R. Smith, B. Schwartz, R. Simantov, and S. Kelley Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discov. 5 2006 835 844
10. S. Keisner, and S. Shah Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma Drugs 71 2011 443 454
11. M. Nieto, J. Borregaard, J. Ersboll, G.J. ten Bosch, B. van Zwieten-Boot, E. Abadie, J.H. Schellens, and F. Pignatti The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the committee for medicinal products for human use Clin. Cancer Res. 17 2011 6608 6614
12. H. Leung, and A. Chan Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis Clin. Ther. 33 2011 708 716
13. C. Porta, C. Paglino, I. Imarisio, C. Canipari, K. Chen, M. Neary, and M.S. Duh Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy BMC Cancer 11 2011 105
14. S. Schmidt, L. Preu, T. Lemcke, F. Totzke, C. Schächtele, M.H.G. Kubbutat, and C. Kunick Dual IGF-1R/SRC inhibitors based on a N′-aroyl-2-(1H-indol-3-yl)-2-oxoacetohydrazide structure Eur. J. Med. Chem. 46 2011 2759 2769
15. N. Tolle, U. Dunkel, L. Oehninger, I. Ott, L. Preu, T. Haase, S. Behrends, P.G. Jones, F. Totzke, C. Schächtele, M.H.G. Kubbutat, and C. Kunick Synthesis and structure of fluorescent chelate boron complexes of 4-anilinomethylidene-1-benzazepine-2,5-dione ligands Synthesis 2011 2848 2858
16. X. Xie, T. Lemcke, R. Gussio, D.W. Zaharevitz, M. Leost, L. Meijer, and C. Kunick Epoxide-containing side chains enhance antiproliferative activity of paullones Eur. J. Med. Chem. 40 2005 655 661
17. A.-M. Egert-Schmidt, J. Dreher, U. Dunkel, S. Kohfeld, L. Preu, H. Weber, J.E. Ehlert, B. Mutschler, F. Totzke, C. Schächtele, M.H.G. Kubbutat, K. Baumann, and C. Kunick Identification of 2-anilino-9-methoxy-5,7-dihydro-6H- pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation J. Med. Chem. 53 2010 2433 2442
18. A.K. Ghose, T. Herbertz, D.A. Pippin, J.M. Salvino, and J.P. Mallamo Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery J. Med. Chem. 51 2008 5149 5171
19. D. Valdez-Padilla, S. Rodríguez-Morales, A. Hernández- Campos, F. Hernández-Luis, L. Yépez-Mulia, A. Tapia-Contreras, and R. Castillo Synthesis and antiprotozoal activity of novel 1-methylbenzimidazole derivatives Bioorg. Med. Chem. 17 2009 1724 1730
20. M.R. Shaaban, T.S. Saleh, F.H. Osman, and A.M. Farag Regioselective synthesis of some novel pyrazoles, isoxazoles, pyrazolo[3,4-d]pyridazines and isoxazolo[3,4-d]pyridazines pendant to benzimidazole J. Heterocycl. Chem. 44 2007 177 181
21. M.R. Shaaban, T.S. Saleh, and A.M. Farag Synthesis and antimicrobial evaluation of novel pyrazolo[1,5-a]pyrimidine, triazolo[1,5-a]pyrimidine and pyrimido[1,2-a]benzimidazole derivatives Heterocycles 71 2007 1765 1777
22. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612
23. J.J.E.M. Kitzen, M.J.A. de Jonge, and J. Verweij Aurora kinase inhibitors Crit. Rev. Oncol. Hematol. 73 2010 99 110
24. H. Katayama, W.R. Brinkley, and S. Sen The aurora kinases: role in cell transformation and tumorigenesis Cancer Metastasis Rev. 22 2003 451 464
25. G. Vader, and S.M.A. Lens The Aurora kinase family in cell division and cancer Biochim. Biophys. Acta 1786 2008 60 72
26. K. Strebhardt, and A. Ullrich Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 6 2006 321 330
27. M. Kothe, D. Kohls, S. Low, R. Coli, A.C. Cheng, S.L. Jacques, T.L. Johnson, C. Lewis, C. Loh, J. Nonomiya, A.L. Sheils, K.A. Verdries, T.A. Wynn, C. Kuhn, and Y.H. Ding Structure of the catalytic domain of human polo-like kinase 1 Biochemistry 46 2007 5960 5971
28. S. Sur, R. Pagliarini, F. Bunz, C. Rago, L.J. Diaz, K. Kinzler, B. Vogelstein, and N. Papadopoulos A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 Proc. Natl. Acad. Sci. U.S.A. 106 2009 3964 3969
29. C. McInnes, and M. Wyatt PLK1 as an oncology target: current status and future potential Drug Discov. Today 16 2011 619 625
30. H. Hao, Y. Naomoto, X. Bao, N. Watanabe, K. Sakurama, K. Noma, T. Motoki, Y. Tomono, T. Fukazawa, Y. Shirakawa, T. Yamatsuji, J. Matsuoka, Z. Wang, and M. Takaoka Focal adhesion kinase as potential target for cancer therapy Oncol. Rep. 22 2009 973 979
31. V. Golubovskaya, K. Conway-Dorsey, S. Edmiston, C. Tse, A. Lark, C. Livasy, D. Moore, R. Millikan, and W. Cance FAK overexpression and p53 mutations are highly correlated in human breast cancer Int. J. Cancer 125 2009 1735 1738
32. B. Tavora, S. Batista, L.E. Reynolds, S. Jadeja, S. Robinson, V. Kostourou, I. Hart, M. Fruttiger, M. Parsons, and K.M. Hodivala-Dilke Endothelial FAK is required for tumour angiogenesis EMBO Mol. Med. 2 2010 516 528
33. R. Abu-Ghazaleh, J. Kabir, H. Jia, M. Lobo, and I. Zachary Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells Biochem. J. 360 2001 255 264
34. M. Cabrita, L. Jones, J. Quizi, L. Sabourin, B. McKay, and C. Addison Focal adhesion kinase inhibitors are potent anti-angiogenic agents Mol. Oncol. 5 2011 517 526
35. J. Folkman What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82 1990 4 6
36. J. McIntyre Sunitinib malate Drugs Fut. 30 2005 785 792
37. M. Press, and H. Lenz EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs 67 2007 2045 2075
38. M. Gilbert, S. Mousa, and S. Mousa Current status of anti-vascular endothelial growth factor (VEGF) stategies and future directions Drugs Fut. 33 2008 515 525
39. T. Underiner, B. Ruggeri, and D. Gingrich Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy Curr. Med. Chem. 11 2004 731 745
40. H. Zhong, and J. Bowen Molecular design and clinical development of VEGFR kinase inhibitors Curr. Top. Med. Chem. 7 2007 379 393
41. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823
42. M.R. Boyd, and K.D. Paull Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen Drug Dev. Res. 34 1995 91 109
43. K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein, J. Plowman, and M.R. Boyd Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of meangraph and COMPARE algorithm J. Natl. Cancer Inst. 81 1989 1088 1092
44. A. Andreani, S. Burnelli, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli, L. Landi, C. Prata, M. Berridge, C. Grasso, H. Fiebig, G. Kelter, A. Burger, and M. Kunkel Antitumor activity of bis-indole derivatives J. Med. Chem. 51 2008 4563 4570
45. C. Kunick, C. Bleeker, C. Prühs, F. Totzke, C. Schächtele, M.H.G. Kubbutat, and A. Link Matrix compare analysis discriminates subtle structural differences in a family of novel antiproliferative agents, diaryl-3-hydroxy-2,3,3a,10a-tetrahydrobenzo[b]cyclopenta[e]azepine-4,10(1H,5H) -diones Bioorg. Med. Chem. Lett. 16 2006 2148 2153
46. FRED, Version 2.2.5 2011 OpenEye Scientific Software, Inc. Santa Fe, NM, USA
47. PyMOL Molecular Graphics System, Version 1.2r1, Schrödinger, LLC, New York, USA.
48. OMEGA, Version 2.3.2, OpenEye Scientific Software, Inc., Santa Fe, NM, USA.
49. MOE, Version 2010.10 2010 ChemComp Montreal, Canada
50. C. Reichwald, O. Shimony, U. Dunkel, N. Sacerdoti-Sierra, C.L. Jaffe, and C. Kunick 2-(3-Aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype J. Med. Chem. 51 2008 659 665
51. F. Tavares, J. Boucheron, S. Dickerson, R. Griffin, F. Preugschat, S. Thomson, T. Wang, and H. Zhou N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin- 2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy J. Med. Chem. 47 2004 4716 4730
52. J. Zhang, T. Chung, and K. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73
53. http://dtp.nci.nih.gov/branches/btb/ivclsp.html (accessed September 2010).
54. M.R. Grever, S.A. Schepartz, and B.A. Chabner The National Cancer Institute: cancer drug discovery and development program Semin. Oncol. 19 1992 622 638
55. J. Kirchmair, G. Wolber, C. Laggner, and T. Langer Comparative performance assessment of the conformational model generators omega and catalyst: a large-scale survey on the retrieval of protein-bound ligand conformation J. Chem. Inf. Model. 46 2006 1848 1861